Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of COVID-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.
In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.
"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Poonawalla said in a tweet.
Mumbai Railway Police Transfers 8 Constables Amid Extortion Probe; New Bag-Checking Guidelines To Be Issued Soon
Energetic! Novak Djokovic Lets Out Thunderous Roar After Breaking Carlos Alcaraz's Serve In US Open 2025 Semifinal; Video
Audacious! Carlos Alcaraz's Reaction To Novak Djokovic's Backhand Shot Goes Viral During US Open 2025 Semifinal Match; Video
BJP-NDA Headed For One-Sided Victory In Bihar Polls: UP Deputy CM Keshav Prasad Maurya
